JAN 13 2006

TRABE

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **TRANSMITTAL**

FORM

(to be used for all correspondence after initial filing)

7

Total Number of Pages in This Submission

Application Number	10/608,372	
Filing Date	June 27, 2003	
First Named Inventor	Sung-Soo PARK	
Art Unit	1651	
Examiner Name	Leon B. LANKFORD, JR.	
Attorney Docket Number	75766.010400/US	

ENCLOSURES (Check all that apply)				
Fee Transmittal Form	Drawing(s)	After Allowance Communication to TC		
Fee Attached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences		
Amendment/Reply	Petition	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)		
After Final	Petition to Convert to a Provisional Application	Proprietary Information		
Affidavits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address	Status Letter Other Enclosure(s) (please Identify		
Extension of Time Request	Terminal Disclaimer	below): Return Prepaid Postcard		
Express Abandonment Request	Request for Refund			
Information Disclosure Statement	CD, Number of CD(s) Landscape Table on CD			
Certified Copy of Priority Document(s)	Remarks			
Response to Missing Parts/ Incomplete Application				
Response to Missing Parts under 37 CFR 1.52 or 1.53				
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT				
Firm Name Greenberg Traurig LLF Signature				
Printed name Peter J. Gluck				
Date 1-13-06	Reg	No. 38,022		
CERTIFICATE OF TRANSMISSION/MAILING				
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.				
Signature / Notites Manbles				
Typed or printed name Dorothy L. Chambe	ers	Date 1-13-06		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. Do NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

JAN 13 2006

75766.010500/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Sung-Soo PARK

Examiner:

Leon B.

LANKFORD, JR.

Serial No.

10/608,372

Group Art Unit:

1651

Filed:

June 27, 2003

Docket No.

75766.010400/US

Title:

BIO-ARTIFICIAL LIVER SYSTEM

Customer No.: 33,717

CERTIFICATE UNDER 37 CFR 1.10

'Express Mail' mailing label number: EV 688771816 US

Date of Deposit: January 13, 2006

I hereby certify that this paper or fee is being deposited with the United States Postal Service 'Express Mail Post Office To Addressee' service under 37 CFR 1.10 and is addressed to MAIL STOP: AMENDMENT, Commissioner for Patent 22313-1450.

RESPONSE TO ELECTION OF SPECIES MAILED 12/13/2005

MAIL STOP: AMENDMENT Hon. Commissioner for Patents Post Office Box 1450

Alexandria, Virginia 22313-1450

Dear Sir:

In response to the Office Action mailed December 13, 2005, Applicant respectfully elects Group I, viz. claims 1 - 14 [sic*] which the Examiner states are drawn to a bio-artificial liver, classified in class 435, subclass 303.1. This restriction is done provisionally, and with traverse, in that applicant's system can be used for detoxification of plasma from a mammal and that is the subject matter toward which the instant applications' claims have been directed, as well as the currently pending submission to the U.S. Food and Drug Administration.

*A telephone call was placed to the Examiner pointing out that claims 1-13 ostensively comprise the "system," however 14 was inadvertently included.

While the Examiner points out other usages that he hypothecates the methods of group II and group III could be used for, no comment is offered for consideration by applicant at this time as to these representations, as none is seen as salient in order to advance prosecution in this important subject matter, advancing the likelihood of clinical progress and the support of ameliorated and otherwise enhanced patient outcomes using said technology.

The remaining claims are withdrawn, without prejudice and maintaining all divisional rights. Remarks begin on page 6. It is respectfully requested that this case is in a condition for allowance and such relief is hereby earnestly solicited.

A complete listing of the claims follows, and kindly withdraw claims 14 - 18, without prejudice.